Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Posted on by Phenomenological Research Awards

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist Award 

Dermatologist at The First Hospital of Jilin University | China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award

Posted on by Phenomenological Research Awards

Dr. Javier Baena Espinar | Medicine and Dentistry | Best Research Article Award 

Medical Oncologist at Hospital 12 de Octubre | Spain

Dr. Javier Baena Espinar is a prominent medical oncology researcher whose work has significantly shaped contemporary understanding of thoracic malignancies, precision oncology, and real-world clinical outcomes. His academic background is grounded in advanced training in health sciences, biomedicine, molecular oncology, immuno-oncology, and cancer biology, supported by multiple postgraduate degrees and specialized certifications that have strengthened his expertise in lung cancer research and evidence-based clinical practice. His professional experience spans leading Spanish healthcare and research institutions, where he has contributed to multidisciplinary oncology teams, national research initiatives, and international collaborative networks focused on improving diagnostic accuracy, treatment personalization, and therapeutic decision-making. His research interests center on non-small cell lung cancer, small cell lung cancer, immune checkpoint inhibitors, next-generation sequencing, biomarker discovery, outcomes research, and the intersection between cancer care and infectious disease vulnerabilities. He has been instrumental in studies evaluating immunotherapy effectiveness, prognostic determinants, molecular profiling, and global registry data, producing findings that support the optimization of treatment strategies and guide clinical standards. With 27 published documents, 884 citations from 800 referencing articles, and an h-index of 11, his scholarly contributions reflect sustained impact and influence across oncology and translational research communities. His work appears in high-impact journals and encompasses both clinical and translational dimensions, bridging innovative scientific methodologies with real-world applicability. Through continuous involvement in international collaborations, multicenter studies, and academic dissemination, he has advanced the understanding of patient outcomes, therapeutic safety, and emerging frontiers in cancer treatment. His research trajectory demonstrates a strong commitment to expanding precision medicine, fostering collaborative research excellence, and improving the clinical management of thoracic cancers. Dr. Javier Baena Espinar’s ongoing contributions highlight his dedication to advancing scientific knowledge, strengthening global oncology evidence, and supporting the evolution of patient-centered cancer care.

Profile: Scopus | Orcid

Featured Publications:

  • Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.

  • Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.

  • Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.

  • Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.

  • Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.

  • Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.

  • Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.

  • Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.

  • Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.

  • Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.

  • Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.

  • Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.

  • Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.

Tom Schimanski | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research Awards

Mr. Tom Schimanski | Medicine and Dentistry | Best Researcher Award  

Student at Universität Regensburg | Germany

Mr. Tom Schimanski is an emerging researcher at Universität Regensburg whose work bridges the intersection of medicine, surgery and biomedical innovation. His academic background reflects an early commitment to scientific rigor and medical advancement, culminating in advanced studies and a doctoral research focus within the Department of Plastic, Hand, and Reconstructive Surgery. Building upon a foundation of clinical training, he has developed extensive expertise in translational medicine, integrating laboratory research with real-world surgical applications. His scholarly engagement is marked by active participation in experimental studies addressing tissue regeneration, cellular responses, and cryopreservation methodologies for adipose and connective tissues. Mr. Tom Schimanski’s contributions to the scientific community are evident through his publications in internationally indexed journals such as Cells, where his research explores mechanisms of ferroptosis, biocompatibility of anesthetics, exosome mediated cellular communication, and innovative imaging approaches like multispectral optoacoustic tomography. With 3 published documents, 1 citation, and an h-index of 1, he exemplifies the diligence and precision of a young scientist dedicated to building a lasting impact in medical science. His ongoing collaborations with institutions such as Helmholtz Zentrum München further strengthen his multidisciplinary approach, combining cellular biology, materials science, and reconstructive medicine. Mr. Tom Schimanski’s research interests encompass tissue engineering, regenerative medicine, biomaterials development, and translational surgery, focusing on developing clinically viable strategies to enhance wound healing and graft preservation. His work also reflects a broader vision for integrating biotechnological innovations into surgical practice, fostering advancements that align patient safety with scientific discovery. Through his deep engagement in both experimental and clinical contexts, he continues to advance methodologies that could redefine regenerative outcomes and improve the sustainability of reconstructive procedures. With a growing research record and a strong foundation in evidence-based medicine, Mr. Tom Schimanski represents a new generation of clinician-scientists whose contributions are shaping the evolving landscape of biomedical research and surgical innovation. His pursuit of excellence underscores a commitment to translating science into tangible medical progress, marking him as a promising and impactful figure in contemporary medical research.

Profile: Scopus | Orcid

Featured Publications:

Schimanski, T., Loucas, R., Loucas, M., Brébant, V., Anker, A., Klein, S., Diesch, S. T., Pagani, A., & Prantl, L. (2025). Histological and immunohistochemical characteristics of mechanically processed adipose tissue A systematic review and meta-analysis. Cells, 14(21), 1664.

Schimanski, T., Prantl, L., Eigenberger, A., Felthaus, O., Loucas, R., Utpatel, K., & Steer, K. (2025). CELTPLUS fat increases the metabolic activity as well as the SVF-yield significantly when compared to CELT fat, even after cryopreservation with DMSO. Cells, 14(16), 1270.

Schimanski, T., Loucas, R., Loucas, M., Felthaus, O., Brébant, V., Klein, S., Anker, A., Frank, K., Siegmund, A., Pagani, A., & Prantl, L. (2025). Histology and immunohistochemistry of adipose tissue: A scoping review on staining methods and their informative value. Cells, 14(12), 898.

Eigenberger, A., Felthaus, O., Bartsch, A., Schimanski, T., Utpatel, K., & Prantl, L. (2025). The influence of sedimentation on the composition of the lipoaspirate and the effects on further mechanical processing. Cells, 14(8), 601.